09:50 AM EST - Oncolytics Biotech® Inc. : Announced its financial results and operational highlights for the first quarter ended March 31, 2016. At March 31, the Company reported $22.3 million in cash, cash equivalents and short-term investments. At May 5, the Company had approximately $21.4 million in cash, cash equivalents and short-term investments, which is expected to provide sufficient funds to support several small early-stage immunotherapy combination studies as well as both a run-in and a registration study in muscle-invasive bladder cancer. Oncolytics Biotech® Inc.
shares T.ONC are trading up $0.02 at $0.74.
